Table 5

The effects on steatosis of cumulative exposure duration to specific antiretroviral medication in 184 HIV-HCV coinfected patients according to the genotype
All patients (n=184)

Genotype 3

(n=47)

Other genotype

(n=132)

Antiretrovirals

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p
Nucleoside reverse transcriptase inhibitors 1.05 (0.96-1.16) 0.30 1.07 (0.85-1.35) 0.55 1.03 (0.92-1.15) 0.64
zidovudine 1.03 (0.91-1.16) 0.65 1.01 (0.81-1.27) 0.92 1.00 (0.86-1.17) 0.98
lamivudine 1.01 (0.88-1.17) 0.84 0.99 (0.75-1.32) 0.97 0.99 (0.84-1.17) 0.92
stavudine 1.05 (0.90-1.24) 0.54 1.16 (0.81-1.68) 0.41 0.99 (0.81-1.22) 0.94
didanosine 1.04 (0.85-1.27) 0.70 1.08 (0.64-1.81) 0.77 1.04 (0.83-1.29) 0.75
zalcitabine 1.50 (0.68-3.34) 0.31 NE 1.35 (0.57-3.16) 0.49
tenofovir 1.19 (0.69-2.07) 0.53 0.29 (0.03-2.49) 0.26 1.46 (0.80-2.66) 0.22
abacavir 0.98 (0.69-1.41) 0.94 1.14 (0.54-2.41) 0.73 0.88 (0.56-1.41) 0.61
Protease inhibitors 1.06 (0.90-1.25) 0.50 1.14 (0.82-1.59) 0.44 0.98 (0.80-1.21) 0.87
ritonavir 0.96 (0.71-1.28) 0.76 0.88 (0.45-1.74) 0.72 1.00 (0.71-1.40) 0.98
indinavir 1.14 (0.87-1.47) 0.34 NE 0.89 (0.63-1.25) 0.50
nelfinavir 1.12 (0.79-1.59) 0.54 1.06 (0.63-1.76) 0.83 1.11 (0.66-1.87) 0.68
saquinavir 0.72 (0.45-1.14) 0.16 0.67 (0.33-1.36) 0.26 0.54 (0.25-1.19) 0.13
lopinavir-ritonavir 0.86 (0.54-1.37) 0.52 0.90 (0.13-6.28) 0.92 0.89 (0.54-1.46) 0.64
atazanavir 0.99 (0.35-2.81) 0.98 NE 1.53 (0.43-5.47) 0.51
Non-nucleoside reverse transcriptase inhibitors 1.17 (0.88-1.55) 0.27 1.04 (0.60-1.82) 0.89 1.25 (0.90-1.75) 0.18
efavirenz 1.19 (0.88-1.63) 0.26 1.08 (0.56-2.09) 0.82 1.28 (0.89-1.83) 0.18
nevirapine 1.24 (0.77-2.00) 0.36 0.47 (0.19-1.20) 0.57 1.18 (0.67-2.08) 0.56

Adjusted for period of liver biopsy.

Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.

Martinez et al.

Martinez et al. BMC Research Notes 2012 5:180   doi:10.1186/1756-0500-5-180

Open Data